AU2018240375C1 - Hydrogel cross-linked hyaluronic acid prodrug compositions and methods - Google Patents

Hydrogel cross-linked hyaluronic acid prodrug compositions and methods Download PDF

Info

Publication number
AU2018240375C1
AU2018240375C1 AU2018240375A AU2018240375A AU2018240375C1 AU 2018240375 C1 AU2018240375 C1 AU 2018240375C1 AU 2018240375 A AU2018240375 A AU 2018240375A AU 2018240375 A AU2018240375 A AU 2018240375A AU 2018240375 C1 AU2018240375 C1 AU 2018240375C1
Authority
AU
Australia
Prior art keywords
amino acid
antibody
acid sequence
drug
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018240375A
Other languages
English (en)
Other versions
AU2018240375A1 (en
AU2018240375B2 (en
AU2018240375A2 (en
Inventor
Nicola BISEK
Germaine Fuh
Thomas KNAPPE
Patrick Koenig
Burkhardt Laufer
Chingwei Vivian Lee
Harald Rau
Sebastian Stark
Tobias Voigt
Samuel WEISBROD
Daniela Bumbaca YADAV
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ascendis Pharma AS
Original Assignee
Ascendis Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma AS filed Critical Ascendis Pharma AS
Publication of AU2018240375A1 publication Critical patent/AU2018240375A1/en
Publication of AU2018240375A2 publication Critical patent/AU2018240375A2/en
Assigned to ASCENDIS PHARMA A/S reassignment ASCENDIS PHARMA A/S Request for Assignment Assignors: ASCENDIS PHARMA A/S, GENENTECH, INC.
Publication of AU2018240375B2 publication Critical patent/AU2018240375B2/en
Application granted granted Critical
Publication of AU2018240375C1 publication Critical patent/AU2018240375C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
AU2018240375A 2017-03-22 2018-03-22 Hydrogel cross-linked hyaluronic acid prodrug compositions and methods Active AU2018240375C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762475094P 2017-03-22 2017-03-22
US62/475,094 2017-03-22
PCT/US2018/023857 WO2018175788A1 (en) 2017-03-22 2018-03-22 Hydrogel cross-linked hyaluronic acid prodrug compositions and methods

Publications (4)

Publication Number Publication Date
AU2018240375A1 AU2018240375A1 (en) 2019-09-26
AU2018240375A2 AU2018240375A2 (en) 2020-03-05
AU2018240375B2 AU2018240375B2 (en) 2023-08-03
AU2018240375C1 true AU2018240375C1 (en) 2024-02-01

Family

ID=61906882

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018240375A Active AU2018240375C1 (en) 2017-03-22 2018-03-22 Hydrogel cross-linked hyaluronic acid prodrug compositions and methods

Country Status (14)

Country Link
US (3) US11642415B2 (cg-RX-API-DMAC7.html)
EP (1) EP3600441A1 (cg-RX-API-DMAC7.html)
JP (2) JP7216006B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240150530A (cg-RX-API-DMAC7.html)
CN (1) CN110891611B (cg-RX-API-DMAC7.html)
AR (1) AR111190A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018240375C1 (cg-RX-API-DMAC7.html)
CA (1) CA3055985A1 (cg-RX-API-DMAC7.html)
IL (1) IL269506B2 (cg-RX-API-DMAC7.html)
MA (1) MA49265A (cg-RX-API-DMAC7.html)
SG (2) SG11201908547VA (cg-RX-API-DMAC7.html)
TW (1) TWI857935B (cg-RX-API-DMAC7.html)
WO (1) WO2018175788A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201905930B (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
AR111190A1 (es) * 2017-03-22 2019-06-12 Genentech Inc Composiciones en hidrogel de prodrogas entrecruzadas de ácido hialurónico y métodos relacionados
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
MA52662A (fr) 2018-03-28 2021-02-17 Ascendis Pharma Oncology Div A/S Conjugués d'il-2
US20210008168A1 (en) 2018-03-28 2021-01-14 Ascendis Pharma A/S Conjugates
EP3856257A1 (en) * 2018-09-26 2021-08-04 Ascendis Pharma A/S Degradable hyaluronic acid hydrogels
CA3125533A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma Oncology Division A/S Conjugates of pattern recognition receptor agonists
WO2020141223A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma A/S Induction of sustained local inflammation
CA3125541A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma Oncology Division A/S Minimization of systemic inflammation
US20220054476A1 (en) 2019-01-04 2022-02-24 Ascendis Pharma Oncology Division A/S Sustained local drug levels for innate immune agonists
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
US20220305136A1 (en) 2019-06-21 2022-09-29 Ascendis Pharma Oncology Division A/S Anti-ctla4 conjugates
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
US20230102309A1 (en) 2019-06-21 2023-03-30 Ascendis Pharma Oncology Division A/S Tyrosine kinase inhibitor conjugates
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4084872A1 (en) 2020-01-03 2022-11-09 Ascendis Pharma A/S Conjugates undergoing intramolecular rearrangements
AU2021269007A1 (en) 2020-05-04 2022-11-24 Ascendis Pharma A/S Hydrogel irradiation
US12428461B2 (en) 2020-06-03 2025-09-30 Ascendis Pharma Oncology Division A/S Treating cancer with a conjugate comprising an IL-2 moiety
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
EP4204439A1 (en) 2020-08-28 2023-07-05 Ascendis Pharma Oncology Division A/S Glycosylated il-2 proteins and uses thereof
BR112023018802A2 (pt) 2021-04-01 2023-10-31 Ascendis Pharma As Uso de hormônio de crescimento de ação prolongada para o tratamento de doenças induzidas por inflamação
CN116059312A (zh) * 2021-07-23 2023-05-05 百奥泰生物制药股份有限公司 整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用
KR20240122846A (ko) 2021-12-13 2024-08-13 아센디스 파마 온콜로지 디비전 에이/에스 Tlr7/8 아고니스트를 이용한 암 치료
AU2023254113A1 (en) * 2022-04-15 2024-10-24 Valitor, Inc. Purified multivalent protein-hyaluronic acid polymer conjugates
CN115389681B (zh) * 2022-11-01 2023-01-20 常州百瑞吉生物医药有限公司 一种巯基化透明质酸衍生物中二硫苏糖醇残留的检测方法
TW202434299A (zh) 2023-01-05 2024-09-01 丹麥商阿仙帝斯製藥公司 製造水凝膠微球之方法
TW202430223A (zh) 2023-01-05 2024-08-01 丹麥商阿仙帝斯眼科製藥有限公司 用於治療眼部病症之藥物結合物
TW202440150A (zh) 2023-03-06 2024-10-16 丹麥商阿仙帝斯製藥公司 具白蛋白結合部分之藥物化合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016193371A1 (en) * 2015-06-05 2016-12-08 Sanofi Prodrugs comprising an glp-1/glucagon dual agonist linker hyaluronic acid conjugate

Family Cites Families (235)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4716224A (en) 1984-05-04 1987-12-29 Seikagaku Kogyo Co. Ltd. Crosslinked hyaluronic acid and its use
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4937270A (en) 1987-09-18 1990-06-26 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
EP0326111A3 (en) 1988-01-29 1989-12-27 New York Blood Center, Inc. Peptide derivatives rendered immunogenic when administered with alum as an adjuvant
IT1219587B (it) 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
SE8900422D0 (sv) 1989-02-08 1989-02-08 Pharmacia Ab Tvaerbundna hyaluronatgeler samt foerfarande foer framstaellning av dessa
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5356883A (en) 1989-08-01 1994-10-18 Research Foundation Of State University Of N.Y. Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP1120112A3 (en) 1990-06-14 2001-11-14 Integra LifeSciences Corporation Wound dressing and drug delivery device
US5474767A (en) 1990-07-26 1995-12-12 Monsanto Company Polyamines and method for preparation thereof
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5144088A (en) 1991-04-26 1992-09-01 Aristech Chemical Corporation Manufacture of neopentyl glycol (I)
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5837747A (en) 1991-10-29 1998-11-17 Vivorx, Inc. Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
GB9216925D0 (en) 1992-08-10 1992-09-23 Royal Holloway Microspheres of polyhydroxylic materials
JP3107488B2 (ja) 1993-09-29 2000-11-06 株式会社資生堂 架橋ヒアルロン酸を用いた徐放性製剤及び塞栓剤
US5658592A (en) 1994-05-13 1997-08-19 Kuraray Co., Ltd. Medical crosslinked polymer gel of carboxylic polysaccharide and diaminoalkane
US6063396A (en) 1994-10-26 2000-05-16 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5690961A (en) 1994-12-22 1997-11-25 Hercules Incorporated Acidic polysaccharides crosslinked with polycarboxylic acids and their uses
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
IT1281886B1 (it) 1995-05-22 1998-03-03 Fidia Advanced Biopolymers Srl Processo per la preparazione di idrogel ottenuti da derivati chimici dell'acido ialuronico mediante irradiazioni ultraviolette e loro
US5612321A (en) 1995-06-22 1997-03-18 Hercules Incorporated Antioxidant grafted polysaccharides
JP3130234B2 (ja) 1995-09-29 2001-01-31 デンセイ・ラムダ株式会社 インバータ装置
EA200000825A1 (ru) 1996-02-09 2001-02-26 Амген Инк. Композиция, включающая ингибитор il-1 и полимер, контролирующий высвобождение
JP4247846B2 (ja) 1997-07-03 2009-04-02 デュピュイ・スパイン・インコーポレーテッド 架橋ポリサッカリド薬物キャリア
JPH1133104A (ja) 1997-07-16 1999-02-09 Res Inst For Prod Dev 生体組織への接着性を有する医用材料
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
EP1034298B1 (en) 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
WO1999059603A1 (en) 1998-05-20 1999-11-25 Chugai Seiyaku Kabushiki Kaisha Remedies for joint diseases bound to hyaluronic acid
ITPD980169A1 (it) 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
US6630457B1 (en) 1998-09-18 2003-10-07 Orthogene Llc Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same
JP2000119196A (ja) 1998-10-07 2000-04-25 Menicon Co Ltd 眼科用薬剤徐放材及びその製造方法
IT1303735B1 (it) 1998-11-11 2001-02-23 Falorni Italia Farmaceutici S Acidi ialuronici reticolati e loro usi medici.
JP2002531217A (ja) 1998-12-04 2002-09-24 チャンドラシェカー ピー． パサック， 生体適合性架橋ポリマー
US6472379B1 (en) 1999-03-15 2002-10-29 Trustees Of Boston University Angiogenesis inhibition
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU2574701A (en) 1999-11-26 2001-06-12 Regents Of The University Of Michigan, The Reversible cross-linked hydrogels
US20030180714A1 (en) 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
DE60111637T2 (de) 2000-07-31 2006-05-11 Iscience Corp., San Francisco Biomaterial in Form von Mikropartikeln von Hyaluronsäure zur medizinischen Verwendung
IT1317358B1 (it) 2000-08-31 2003-06-16 Fidia Advanced Biopolymers Srl Derivati cross-linkati dell'acido ialuronico.
DK1355566T3 (da) 2000-12-18 2013-03-04 Univ Texas Lokal regional kemoterapi og radioterapi ved anvendelse af hydrogel in situ
ATE312076T1 (de) 2001-02-22 2005-12-15 Anika Therapeutics Inc Thiol-modifizierte hyaluronan-derivate
ITMI20011238A1 (it) 2001-06-12 2002-12-12 Bartholdy Consultadoria E Serv Polimeri polisaccaridici di origine naturale coniugati chimicamente asostanze farmacologicamente o biologicamente attive e loro proprieta'
ITPD20020064A1 (it) 2002-03-12 2003-09-12 Fidia Advanced Biopolymers Srl Derivati esterei dell'acido ialuronico per la preparazione di idrogelda utilizzare in campo biomedico, sanitario e chirurgico e come sistem
WO2003082316A1 (en) 2002-03-29 2003-10-09 The Regents Of The University Of California Microgel particles for the delivery of bioactive materials
JPWO2003084571A1 (ja) 2002-04-08 2005-08-11 電気化学工業株式会社 骨感染症治療用組成物
ES2346646T5 (es) 2002-05-30 2018-02-15 The Scripps Research Institute Ligación catalizada con cobre de azidas y acetilenos
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
KR100507545B1 (ko) 2002-09-03 2005-08-09 주식회사 엘지생명과학 히알루론산 유도체 및 그의 제조방법
JP5156890B2 (ja) 2002-09-11 2013-03-06 独立行政法人物質・材料研究機構 高分子架橋体及びその製造方法
US7816316B2 (en) 2002-11-21 2010-10-19 Chugai Seiyaku Kabushiki Kaisha Sustained release drug carrier
CA2509382A1 (en) 2002-12-17 2004-07-08 Todd C. Zion Stimuli-responsive systems for controlled drug delivery
EP1585767A2 (en) 2003-01-16 2005-10-19 Genentech, Inc. Synthetic antibody phage libraries
EP1631375B1 (en) 2003-01-17 2011-11-02 Cornell Research Foundation, Inc. Injectable hydrogel microspheres from aqueous two-phase system
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
CA2521784C (en) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
AU2003901834A0 (en) 2003-04-17 2003-05-01 Clearcoll Pty Ltd Cross-linked polysaccharide compositions
CA2523246C (en) 2003-04-25 2009-12-01 Kos Life Sciences, Inc. Formation of strong superporous hydrogels
JP2004323454A (ja) 2003-04-25 2004-11-18 Chisso Corp 薬剤
WO2005044853A2 (en) * 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US8153591B2 (en) 2003-08-26 2012-04-10 Gel-Del Technologies, Inc. Protein biomaterials and biocoacervates and methods of making and using thereof
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
US8124120B2 (en) 2003-12-22 2012-02-28 Anika Therapeutics, Inc. Crosslinked hyaluronic acid compositions for tissue augmentation
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile
HUE045882T2 (hu) 2004-03-23 2020-01-28 Ascendis Pharma Gmbh Polimer prodrug önmagát lehasító linkerrel
BRPI0508761A (pt) 2004-03-31 2007-08-14 Genentech Inc anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US8293890B2 (en) 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
US20050244472A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
GB0411583D0 (en) 2004-05-24 2004-06-23 Univ Bath Process
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
WO2006113668A1 (en) 2005-04-15 2006-10-26 University Of South Florida A method of transdermal drug delivery using hyaluronic acid nanoparticles
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
WO2007004675A1 (ja) 2005-07-06 2007-01-11 Seikagaku Corporation 薬剤導入光架橋ヒアルロン酸誘導体ゲル
US8679536B2 (en) 2005-08-24 2014-03-25 Actamax Surgical Materials, Llc Aldol-crosslinked polymeric hydrogel adhesives
RU2472809C2 (ru) 2005-09-02 2013-01-20 Колбар Лайфсайенс Лтд. Поперечно сшитые полисахаридные и белковые матрицы и способы их получения
KR20080067619A (ko) 2005-09-15 2008-07-21 유니버시티 오브 유타 리써치 파운데이션 고분자 조성물 및 이의 제조방법, 및 이의 용도
EP1928825A1 (en) 2005-09-21 2008-06-11 Universiteit van Amsterdam Novel cross-linkers for obtaining structure information on molecule complexes
CN103120701B (zh) 2005-10-12 2014-11-05 生化学工业株式会社 包含疏水基团结合型糖胺聚糖在制备预防或治疗角膜上皮层病症的药物中的用途
US20070099820A1 (en) 2005-10-19 2007-05-03 Smartcells, Inc. Polymer-drug conjugates
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EP1968498A2 (en) 2005-12-14 2008-09-17 Anika Therapeutics Inc. Meniscal implant of hyaluronic acid derivatives for treatment of meniscal defects
US7879818B2 (en) 2005-12-23 2011-02-01 Janos Borbely Hyaluronic acid-based cross-linked nanoparticles
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
WO2007124132A2 (en) 2006-04-20 2007-11-01 University Of Utah Research Foundation Polymeric compositions and methods of making and using thereof
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
ITMI20061726A1 (it) 2006-09-11 2008-03-12 Fidia Farmaceutici Derivati crosslinkati a base di acido ialuronico reticolato via click chemistry
CA2662978A1 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
JP5694664B2 (ja) 2006-09-29 2015-04-01 サーモディクス，インコーポレイティド 生分解性眼用インプラント及び眼の病気を治療する方法
EP1942117A1 (en) 2006-12-29 2008-07-09 Sigea S.R.L. Derivatives of acid polysaccharides
KR20080073419A (ko) 2007-02-06 2008-08-11 주식회사 핸슨바이오텍 의료용 히알루론산 유도체 마이크로비드 및 이의 제조 방법
EP1992364A1 (en) 2007-05-16 2008-11-19 Biosuma S.r.l. Carboxylated polysaccharides phosphated or bisphosphonated derivatives, optionally cross-linked, and their preparation and biomedical uses
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
JP2010533202A (ja) 2007-07-11 2010-10-21 エンゾン ファーマシューティカルズ，インコーポレーテッド 多置換芳香族部分を含むポリマー性薬剤送達システム
US8318695B2 (en) 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
EP2090592A1 (en) 2007-07-31 2009-08-19 OctoPlus Sciences B.V. Biodegradable hydrogels based on click chemistry
KR101062320B1 (ko) 2007-08-01 2011-09-05 포항공과대학교 산학협력단 가교결합성 히알루론산 유도체 제조방법 및 그 히알루론산유도체의 가교결합물
MX2010001629A (es) 2007-08-10 2010-08-09 Alessandro Sannino Hidrogeles de polimero y metodos de preparacion de los mismos.
US20100210509A1 (en) 2007-10-09 2010-08-19 Postech Academy-Industry Foundation Long acting hyaluronic acid - peptide conjugate
US9522218B2 (en) 2007-10-11 2016-12-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for preparing porous scaffold for tissue engineering, cell culture and cell delivery
ES2405774T3 (es) 2007-10-11 2013-06-03 Inserm (Institut National De La Sante Et De La Recherche Scientifique) Métodos para preparar andamio poroso para la ingeniería de tejidos
US20090143348A1 (en) 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US9109051B2 (en) 2007-12-19 2015-08-18 Evonik Goldschmidt Gmbh Crosslinked hyaluronic acid in emulsion
US20100279952A1 (en) 2007-12-21 2010-11-04 Ninus Caram-Lelham Cross-linked hydrogel containing an active substance
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
HUE044174T2 (hu) 2008-02-01 2019-10-28 Ascendis Pharma As Önhasítható linkert tartalmazó elõvegyület
IE20080211A1 (en) 2008-03-20 2009-11-25 Nat Univ Ireland Biodegradable nanoshells for delivery of therapeutic and/or imaging molecules
CN101538377A (zh) 2008-03-20 2009-09-23 上海昊海生物科技有限公司 一种交联透明质酸凝胶及其制备方法
WO2009120893A2 (en) 2008-03-28 2009-10-01 The Regents Of The University Of California Polypeptide-polymer conjugates and methods of use thereof
WO2009143412A2 (en) 2008-05-23 2009-11-26 Enzon Pharmaceuticals, Inc. Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
US8450475B2 (en) 2008-08-04 2013-05-28 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
GB0816496D0 (en) 2008-09-10 2008-10-15 Zhao Xiaobin Hyaluronic acid cryogel
CN101721349B (zh) 2008-10-16 2011-07-20 常州百瑞吉生物医药有限公司 可注射原位交联水凝胶及其制备方法和用途
US20100098772A1 (en) 2008-10-21 2010-04-22 Allergan, Inc. Drug delivery systems and methods for treating neovascularization
ITRM20080636A1 (it) 2008-11-28 2010-05-29 Univ Palermo Procedimento per la produzione di derivati funzionalizzati dell acido ialuronico e relativi idrogeli.
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
US11090387B2 (en) 2008-12-22 2021-08-17 The Trustees Of The University Of Pennsylvania Hydrolytically degradable polysaccharide hydrogels
FR2945949B1 (fr) 2009-05-26 2011-05-13 Anteis Sa Hydrogel injectable permettant une supplementation en glycerol dans la peau sur le long terme.
CN102458471A (zh) * 2009-05-28 2012-05-16 葛兰素集团有限公司 用于治疗或预防眼病的TNFα拮抗剂和VEGF拮抗剂的组合
WO2010138074A1 (en) 2009-05-29 2010-12-02 Hilborn Joens Hyaluronic acid based delivery systems
IT1399351B1 (it) 2009-06-16 2013-04-16 Fidia Farmaceutici Procedimento per la sintesi di coniugati di glicosamminoglicani (gag) con molecole biologicamente attive, coniugati polimerici e usi relativi
KR101091028B1 (ko) 2009-07-02 2011-12-09 아주대학교산학협력단 체내 주입형 하이드로젤 및 이의 생의학적 용도
WO2011002888A2 (en) 2009-07-02 2011-01-06 E. I. Du Pont De Nemours And Company Hydrogel tissue adhesive for medical use
WO2011012722A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
PL2459220T3 (pl) 2009-07-31 2021-03-08 Ascendis Pharma A/S Biodegradowalne nierozpuszczalne w wodzie hydrożele na bazie poli(glikolu etylenowego)
JP5937966B2 (ja) 2009-08-11 2016-06-22 エージェンシー フォー サイエンス， テクノロジー アンド リサーチ 生体活性物質の細胞送達のための粒子状ヒアルロン酸製剤
JO3008B1 (ar) 2009-08-13 2016-09-05 Seikagaku Kogyo Co Ltd تركيب صيدلي لتخفيف الألم
KR101103423B1 (ko) 2009-09-04 2012-01-06 아주대학교산학협력단 생체 주입형 조직 접착성 하이드로젤 및 이의 생의학적 용도
US20120282211A1 (en) * 2009-11-24 2012-11-08 Carnegie Mellon University Antibodies and conjugates for modulators of angiogenesis
AU2010334412B2 (en) 2009-12-22 2016-02-04 Lifebond Ltd Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices
US20120289571A1 (en) 2009-12-31 2012-11-15 Enzon Pharmaceuticals, Inc. Polymeric conjugates of aromatic amine containing compounds including releasable urea linker
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
US20130030359A1 (en) 2010-01-22 2013-01-31 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
US20130142731A1 (en) 2010-03-01 2013-06-06 Tau Tona Group LP Threads of cross-linked hyaluronic acid and methods of use thereof
EP2552416B1 (en) 2010-03-29 2017-10-25 Evonik Corporation Compositions and methods for improved retention of a pharmaceutical composition at a local administration site
ES2527536T7 (es) 2010-04-27 2016-03-08 Synaffix B.V. Compuestos de ciclooctina fusionada y su uso en reacciones clic sin metales
US8754190B2 (en) 2010-05-05 2014-06-17 Prolynx Llc Controlled release from macromolecular conjugates
DK2566334T3 (en) 2010-05-05 2018-07-23 Prolynx Llc MANAGED PHARMACEUTICAL RELEASE FROM SOLID CARRIERS
WO2011148116A2 (fr) 2010-05-27 2011-12-01 Laboratoire Idenov Acide hyaluronique modifie, procede de fabrication et utilisations
WO2011163069A2 (en) 2010-06-21 2011-12-29 The Trustees Of The University Of Pennsylvania Protease triggered release of molecules from hydrogels
EP2585586B1 (en) 2010-06-22 2017-03-22 Universite de Rouen Improved crosslinked hyaluronan hydrogels for 3d cell culture
IT1401498B1 (it) 2010-07-30 2013-07-26 Mero Srl Idrogelo a base di acido ialuronico e suo uso in ortopedia
CA2815141A1 (en) 2010-10-20 2012-04-26 Tautona Group Lp Threads of cross-linked hyaluronic acid and methods of preparation and use thereof
FR2967677B1 (fr) 2010-11-18 2014-05-16 Centre Nat Rech Scient Derives de polysaccharides comprenant un motif alcene et reaction de couplage par chimie thio-clic
WO2012103445A2 (en) 2011-01-28 2012-08-02 The Regents Of The University Of Colorado, A Body Corporate Convalently cross linked hydrogels and methods of making and using same
JP6141180B2 (ja) 2011-03-03 2017-06-07 中外製薬株式会社 アミノ−カルボン酸により修飾されたヒアルロン酸誘導体
CZ304072B6 (cs) 2011-04-26 2013-09-25 Contipro Biotech S.R.O. Amfoterní materiál na bázi sítované kyseliny hyaluronové, zpusob jeho prípravy, materiály obsahující aktivní cinidla uzavrené v síti hyaluronanu, zpusob jejich prípravy a jejich pouzití
ES2685327T3 (es) 2011-04-28 2018-10-08 President And Fellows Of Harvard College Armazones tridimensionales macroscópicos preformados inyectables para administración mínimamente invasiva
JPWO2012165462A1 (ja) 2011-05-31 2015-02-23 国立大学法人 東京大学 ハイドロゲル及びその製造方法
KR102154944B1 (ko) 2011-06-03 2020-09-11 알러간 인더스트리 에스에이에스 항산화제를 포함하는 피부 충전제 조성물
CN102226009B (zh) 2011-06-09 2013-04-10 西安力邦制药有限公司 一种交联透明质酸凝胶的制备方法
US9592251B2 (en) 2011-06-16 2017-03-14 The Hong Kong University Of Science And Technology Multi-vinylsulfone containing molecule
US20140249093A1 (en) 2011-08-12 2014-09-04 Ascendis Pharma A/S Carrier-Linked Prodrugs Having Reversible Carboxylic Ester Linkages
US9044515B2 (en) 2011-09-06 2015-06-02 University Of Delaware Chemical conjugates for targeted degradation under reducing conditions
WO2013036857A1 (en) 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
EP2755691B1 (en) 2011-09-07 2018-08-22 Prolynx LLC Hydrogels with biodegradable crosslinking
WO2013036748A1 (en) 2011-09-09 2013-03-14 Berry, Lana, L. Bicyclo[6.1.0]non-4-yne reagents for chemical modification of oligonucleotides
WO2013055832A1 (en) 2011-10-11 2013-04-18 Tautona Group Lp Threads of cross-linked hyaluronic acid and methods of use thereof
MX2014003993A (es) * 2011-10-12 2014-08-08 Ascendis Pharma Ophthalmology Division As Prevencion y tratamiento de condiciones oculares.
WO2013071216A1 (en) 2011-11-11 2013-05-16 Miba Medical Inc. Injectable filler
US20140107025A1 (en) 2012-04-16 2014-04-17 Jade Therapeutics, Llc Ocular drug delivery system
US20150087688A1 (en) 2012-04-25 2015-03-26 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
KR101374271B1 (ko) 2012-05-02 2014-03-14 주식회사 제네웰 히알루론산 에폭사이드 가교체 및 그 제조방법
US20150148525A1 (en) 2012-05-18 2015-05-28 Medical Research Council Methods of incorporating an amino acid comprising a bcn group into a polypeptide using an orthogonal codon encoding it and an orthorgonal pylrs synthase
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
CZ304512B6 (cs) 2012-08-08 2014-06-11 Contipro Biotech S.R.O. Derivát kyseliny hyaluronové, způsob jeho přípravy, způsob jeho modifikace a použití
US9827321B2 (en) 2012-08-14 2017-11-28 The Trustees Of The University Of Pennsylvania Stabilizing shear-thinning hydrogels
KR101445265B1 (ko) 2012-09-18 2014-09-30 포항공과대학교 산학협력단 히알루론산-핵산 접합체 및 이를 포함하는 핵산 전달용 조성물
WO2014048564A1 (en) 2012-09-25 2014-04-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. "novel cross-linkers for hydrogels, hydrogels including these cross-linkers and applications thereof"
CN104755103A (zh) 2012-10-11 2015-07-01 阿森迪斯药物眼科部股份有限公司 用于治疗眼病症的中和vegf的前药
CN102942699B (zh) 2012-10-26 2014-07-02 暨南大学 一种自增强双交联透明质酸水凝胶及其制备方法
CN102911380B (zh) 2012-10-29 2015-03-18 北京爱美客生物科技有限公司 透明质酸与生物可降解高分子改性材料及制备方法
WO2014169301A1 (en) 2013-04-12 2014-10-16 Bui The Duy Systems and methods for delivering cross-linked halyuronic acid into a patient
EP2727597A1 (en) 2012-11-06 2014-05-07 Centre National de la Recherche Scientifique (CNRS) Glucose responsive hydrogel comprising pba-grafted hyaluronic acid (ha)
ITPD20120360A1 (it) 2012-11-30 2014-05-31 Fidia Farmaceutici "nuovi geli viscoelastici in chirurgia oftalmica"
MX2015007931A (es) 2012-12-18 2015-10-05 Novartis Ag Composiciones y metodos que utilizan una etiqueta de peptido que se une a hialuronano.
WO2014096257A1 (en) 2012-12-19 2014-06-26 Novozymes Biopharma Dk A/S Freeze-dried cross-linked hyaluronic acid sponge
US9498539B2 (en) 2012-12-27 2016-11-22 Molly Sandra Shoichet Affinity-based controlled release system
US9452138B2 (en) 2012-12-28 2016-09-27 Abbott Cardiovascular Systems Inc. Delivery of biologic therapeutics
WO2014127418A1 (en) 2013-02-20 2014-08-28 The University Of Queensland Conjugate compound and uses of same
CA2905610C (en) 2013-03-14 2021-06-01 Anacoti Ltd. Hyaluronic acid derivatives
MX2015013755A (es) 2013-03-27 2016-05-31 Ct Hospitalier Universitaire Vaudois C H U V Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
KR102049568B1 (ko) 2013-04-01 2019-11-27 삼성전자주식회사 히알루론산을 포함하는 핵산전달용 조성물
WO2014169299A1 (en) 2013-04-12 2014-10-16 Bui The Duy Temperature-release catalyst for cross-linking halyuronic acid during injection
US20150190517A1 (en) 2013-04-12 2015-07-09 Miba Medical Inc. Systems and methods for delivering cross-linked halyuronic acid into a patient
US20160228603A1 (en) 2013-04-12 2016-08-11 Miba Medical Inc. Body augmentation device
HK1221418A1 (zh) * 2013-04-22 2017-06-02 Ascendis Pharma A/S 释放修饰药物的水凝胶-连接的前药
CA2910325A1 (en) 2013-04-25 2014-10-30 Aluron Biopharma Inc. Crosslinked hyaluronic acid compositions
US10137199B2 (en) 2013-05-14 2018-11-27 Biotime, Inc. Thiolated hyaluronan-based hydrogels cross-linked using oxidized glutathione
WO2014198406A1 (en) 2013-06-11 2014-12-18 Anteis S.A. Method for crosslinking hyaluronic acid; method for preparing an injectable hydrogel; hydrogel obtained; use of the obtained hydrogel
WO2014198683A2 (en) 2013-06-14 2014-12-18 Galderma S.A. Ha with cyclodextrins
JP6434003B2 (ja) 2013-06-28 2018-12-05 ガルデルマ エス．エー． 成形された架橋ヒアルロン酸生成物を製造するための方法
EP3016634A2 (en) 2013-07-05 2016-05-11 Therakine Biodelivery GmbH Drug-delivery composition for topical applications and injections and ophtalmic formulations, method for manufacturing thereof, and methods for delivery a drug-delivery composition
WO2015048408A1 (en) 2013-09-27 2015-04-02 Virginia Tech Intellectual Properties, Inc. Cross-metathesized polysaccharide derivatives and processes for preparing them
EP3054981B1 (en) 2013-10-08 2020-07-29 Ascendis Pharma A/S Protecting group comprising a purification tag
JPWO2015053282A1 (ja) 2013-10-08 2017-03-09 キユーピー株式会社 カルボキシメチル基含有修飾ヒアルロン酸および／またはその塩の架橋物およびその製造方法
JP5734536B1 (ja) 2013-10-08 2015-06-17 キユーピー株式会社 カルボキシメチル基含有修飾ヒアルロン酸および／またはその塩の架橋物およびその製造方法
US9782345B2 (en) 2013-10-17 2017-10-10 Jade Therapeutics, Inc. Ocular composition and method
KR101459070B1 (ko) 2013-12-09 2014-11-17 (주) 뉴메딕 지속성을 갖는 히알루론산 겔 조성물
JP2017503835A (ja) * 2014-01-23 2017-02-02 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 眼球疾患治療のための組成物及び方法
WO2016020373A1 (en) 2014-08-06 2016-02-11 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
UA122673C2 (uk) 2014-11-07 2020-12-28 Елевен Байотерапьютікс, Інк. Антитіло, що специфічно зв'язується з людським il-6
WO2016196124A2 (en) 2015-05-29 2016-12-08 Ascendis Pharma Inc. Prodrugs comprising a pyroglutamate linker
EP3302569A1 (en) 2015-05-29 2018-04-11 Albatross Technologies Limited Cross-linked hyaluronic acid for drug delivery and pharmaceutical preparation using same
RU2763916C2 (ru) 2015-09-23 2022-01-11 Дженентек, Инк. Оптимизированные варианты анти-vegf антител
ES2925248T3 (es) 2015-12-09 2022-10-14 Univ California Métodos para tratar una enfermedad o un trastorno oculares
TW201832783A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物
AR111190A1 (es) * 2017-03-22 2019-06-12 Genentech Inc Composiciones en hidrogel de prodrogas entrecruzadas de ácido hialurónico y métodos relacionados

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016193371A1 (en) * 2015-06-05 2016-12-08 Sanofi Prodrugs comprising an glp-1/glucagon dual agonist linker hyaluronic acid conjugate

Also Published As

Publication number Publication date
IL269506B2 (en) 2024-04-01
ZA201905930B (en) 2024-01-31
AU2018240375A1 (en) 2019-09-26
IL269506A (en) 2019-11-28
US20250255973A1 (en) 2025-08-14
MA49265A (fr) 2020-02-05
CN110891611A (zh) 2020-03-17
US11642415B2 (en) 2023-05-09
US12246070B2 (en) 2025-03-11
KR20240150530A (ko) 2024-10-15
WO2018175788A1 (en) 2018-09-27
BR112019019658A2 (pt) 2020-04-22
RU2019133326A3 (cg-RX-API-DMAC7.html) 2021-10-19
JP7216006B2 (ja) 2023-01-31
US20200222547A1 (en) 2020-07-16
TWI857935B (zh) 2024-10-11
RU2019133326A (ru) 2021-04-22
SG11201908547VA (en) 2019-10-30
EP3600441A1 (en) 2020-02-05
JP2020515545A (ja) 2020-05-28
AU2018240375B2 (en) 2023-08-03
AU2018240375A2 (en) 2020-03-05
SG10202107829YA (en) 2021-08-30
AR111190A1 (es) 2019-06-12
TW201842936A (zh) 2018-12-16
US20230414770A1 (en) 2023-12-28
IL269506B1 (en) 2023-12-01
KR20200007776A (ko) 2020-01-22
KR102715397B1 (ko) 2024-10-10
CA3055985A1 (en) 2018-09-27
CN110891611B (zh) 2024-03-29
JP2023058511A (ja) 2023-04-25

Similar Documents

Publication Publication Date Title
AU2018240375C1 (en) Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
US11891437B2 (en) Methods of treating ocular disorders by administering a VEGF-binding antibody covalently linked to a hyaluronic acid polymer
ES2690312T3 (es) Anticuerpos biespecíficos anti-VEGF/anti-ANG-2 y su uso en el tratamiento de enfermedades vasculares oculares
CA2992602A1 (en) Optimized variants of anti-vegf antibodies
RU2812787C2 (ru) Пролекарственные композиции на основе гидрогеля поперечно-сшитой гиалуроновой кислоты и способы
BR122022024506B1 (pt) Composições farmacêuticas compreendendo conjugados fármacoácido hialurônico e uso destas na fabricação de um medicamento para tratar uma indicação ocular
BR112019019658B1 (pt) Conjugado de fármaco-ácido hialurônico, seu método de produção, composição farmacêutica e uso da mesma
RU2782355C2 (ru) Оптимизированные композиции антител для лечения заболеваний глаз
HK40016409A (en) Optimized antibody compositions for treatment of ocular disorders
HK40016409B (zh) 用於治疗眼部病症的优化的抗体组合物

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 12 FEB 2020

PC1 Assignment before grant (sect. 113)

Owner name: ASCENDIS PHARMA A/S

Free format text: FORMER APPLICANT(S): ASCENDIS PHARMA A/S; GENENTECH, INC.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 OCT 2023

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 OCT 2023

FGA Letters patent sealed or granted (standard patent)